This naively seems like it should have a large positive impact on the valuation of gene-editing companies, no? Solving the protein-folding problem means that there is one less mountain standing between gene-editing and true nanotech.
This naively seems like it should have a large positive impact on the valuation of gene-editing companies, no? Solving the protein-folding problem means that there is one less mountain standing between gene-editing and true nanotech.